High expression; Associated with poor prognosis; SLC31A1 regulates immunotherapy and chemotherapy resistance in breast cancer; SLC31A1 promotes breast cancer development by activating the PI3K‐PDK1‐AKT signaling pathway and the EMT gene‐phenotype; SLC31A1 increases intracellular copper ions and ROS, inducing DNA damage and death of MDA‐MB‐231 [8, 9, 10, 11, 12, 13, 14]. This evidence concerns the gene SLC31A1 and breast carcinoma.